Here are four notes:
- Michelle Tarver, MD, PhD, a 15-year veteran of the agency, is stepping into a pivotal role as the new director of the FDA’s device division, taking over for Jeffrey Shuren, MD. Dr. Shuren’s tenure was marked by a rapid approval process for medical devices, but he faced ethical concerns because of his ties to the device industry.
- The device division, with a budget of about $790 million and a staff of 2,500, is under a microscope as congressional lawmakers and consumer advocates raise concerns about industry influence.
- Dr. Tarver will face critical challenges, the Times reported, including the regulation of technologies such as brain-computer interfaces, which aim to restore function to individuals with disabilities. Companies such as Neuralink, led by Elon Musk, are developing these devices and have already received FDA approval to conduct human trials.
- The rapid integration of artificial intelligence in medical devices poses further challenges, with critics highlighting potential gaps in the FDA’s oversight, particularly regarding the lack of data on safety and effectiveness for many AI programs, according to the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
